$SUPN Cashflow Statement | Understand Stock

$SUPN

$40.96 +$0.19 (0.47%) Close

$SUPN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Net earnings (loss)
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:
Depreciation and amortization
Navitor investment R&D expense (see Note 5)
Other income from Navitor (see Note 4)
Intangible asset impairment charges
Amortization of deferred financing costs and debt discount
Realized gains from sales of marketable securities
Realized loss (gains) from sales of marketable securities
Amortization of premium/discount on marketable securities
Change in fair value of contingent consideration
Share-based compensation expense
Deferred income tax benefit
Inventory valuation write-down
Payment of contingent consideration
Noncash lease expense
Other noncash adjustments, net
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accrued product returns and rebates
Accounts payable and other liabilities
Payment of contingent consideration

Net cash provided by operating activities
Cash flows from investing activities
Sales and maturities of marketable securities
Acquisition of Sage, net of cash acquired
Investment in Navitor Pharmaceuticals, Inc.
Acquisition of Adamas, net of cash acquired
Distribution from (investment in) Navitor
Purchase of property and equipment and deferred legal fees paid
Purchases of marketable securities
Maturities of marketable securities
Purchases of property and equipment
Deferred legal fees
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from issuance of convertible notes
Convertible notes issuance financing costs
Proceeds from issuance of warrants
Proceeds from Credit Line
Payments on Credit Line
Payment on convertible notes
Proceeds from issuance of common stock
Proceeds from governmental loan and grant
Repayment of acquired Adamas loan
Payments on finance lease liability
Employee taxes paid related to net share settlement of equity awards
Payment of contingent consideration
Net cash provided by (used in) financing activities

Net change in cash, cash equivalents, and restricted cash
Cash and cash equivalents at beginning of year
Cash, cash equivalents, and restricted cash at end of year
Supplemental cash flow information
Cash paid for income taxes

Contingent consideration liability related to acquisitions
Deferred legal fees and fixed assets included in accounts payable and accrued expenses
Lease assets and tenant receivable obtained for new operating leases
Lease assets obtained for new finance lease
Cash paid for interest on debt
Cash paid for Biscayne acquisition
Cash paid for operating leases
Property and equipment additions from utilization of tenant improvement allowance
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets
Cash and cash equivalents
Restricted cash

Comments